1Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr. Psychiatry 1996, 37 : 68
2Mahmoud R, Gianfrancesco F, Grogg A, et al. Differential effects of antipsychotics on type Ⅰ diabetes: findings from a large health plan database. In: 39th annual meeting of the American college of neuropsychopharmacology (ACNP), 2000, 12, 10
3Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics . European Neuropsychopharmacology,2001, 11 : 25
4Cohen S, Chiles J, MacNaughten A. Weight gain associated with clozapine. Am J Psychiatry, 1990, 147 : 503
5Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry,1992, 149 : 689
6Leadbetter R, Shutty M, Pavalonis D, et al. Clozapine-induced weight gain: Prevalence and clinical relevance. Am J Psychiatry,1992, 149 : 68
7Mertens C. Long-term treatment of chronic schizophrenic patients with risperidone. In: Kane JM, editor, Risperidone: Major Progress in Antipsychotic Treatment. Oxford: Oxford Clinical Communications, 1991, 44
8Owens DGC. Extrapyramidal side effects and tolerability of risperidone: A review. J clin Psychiatry, 1994, 55(suppl 5) : 29
9Bernstein JG. Psychotropic drug induced weight gain: Mechanism and management. Clin Neuropharmacol, 1998, 11 : 194
10Rockwell W, Ellinwood EH, Trader D. Psychotropic drugs promoting weight gain: Health risks and treatment implications.South Med, 1983, 76 : 1407
7Rubia G, Gomezdela Camara, Rodriguez - Morales A, et al. Grupo Espaol parael Estudiode la Diabetes en Patients Es- quizofrenicos. Therapy with antipsychotlc drugs as a risk factor for diabetes in schizophreiaia: a case - control study [ J ]. Medlinical, 2006,126 ( 12 ) :441 - 444.
8Connell B. Solution - Focused Therapy [ M ]. London : Sage, 1998:2 - 3.
9De Jon P, Berg IK. Interviewing for solution [ M ]. 2nd ed. Hartford : Wadsworth Group ,2002:2 - 12.
